"Buy on the rumor. Sell on the news.
Some news blob I read I seem to remember put the pps for tbuff after the deal at 1.16. But then prices vary according to the mania surrounding the company.
Tbuff was way over bought earlier this week and end of last. If it drops alot more to way oversold it will be a good buy given the news lately. Likely will drop and base like a coiled spring till q4 when all the action takes place. Those who are impatient will sell now. Those who see a promising future will hold on.
on stockhouse one poster put an analysis out that gives a current value of 27 dollars per shares. Tongue in check with many grains of salt.
Looks like we've run out of overeager buyers for now. Truthfully we were getting a little frothy.
Nevertheless I'm optimistic that this little gem will reward amply down the road.
Well shaft. Of couse it was up to me to buy in or not after checking it out. But I must thank you profusely for brining tbuff to my attention. So far it's been an incredible gainer and I hope an outsized winner additionally in the future. Yeehaw. Always mindfull that I could have made a lot more on conx selling into the ebola mania vs. waiting for the buy out.
Seems like no news ala the hearing. Must have been a bust.
Shaft, you holding onto your tbuff in hopes that the conversion has the potential for larger gains. I m know I wish we had gotten some stock along side the cash for conx shares. Less cap gains tax and more potential future gains.
If you can figure it out....POZEN has formed a new company, to be named Aralez Pharmaceuticals Limited, organized under the laws of Ireland (“Aralez”). An indirect U.S. subsidiary of Aralez will merge with POZEN, with POZEN surviving as a wholly-owned subsidiary of Aralez. Similarly, an indirect Canadian subsidiary of Aralez will acquire Tribute, through a plan of arrangement, with Tribute surviving as a wholly-owned indirect subsidiary of Aralez. At closing, each share of POZEN common stock will be converted into the right to receive one Aralez ordinary share and each common share of Tribute (other than dissenting shares) will be exchanged for 0.1455 Aralez ordinary shares. As a result of the proposed transaction and before giving effect to the contemplated financing, stockholders of POZEN will own approximately 66 percent of Aralez and shareholders of Tribute would own approximately 34 percent of Aralez, in each case prior to giving effect to any exercise of any outstanding options or warrants or vesting and delivery of any restricted stock units of either company after the date hereof. As of June 5, 2015, POZEN had 32.4 million common shares outstanding and 37.5 million fully diluted shares (using treasury stock method) and Tribute had 116.1 million common shares outstanding and 133.3 million fully diluted shares (using treasury stock method). The transaction will be taxable to the POZEN stockholders and Tribute shareholders. Upon closing, it is expected that Aralez will re-register as a public limited company in Ireland and be named Aralez Pharmaceuticals plc. Aralez will apply to list its ordinary shares on NASDAQ and the TSX.